CAR T-cell therapy positively benefitted patients with patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Breyanzi (lisocabtagene maraleucel), ...

Credit: Bristol Myers Squibb. The approval was based on data from the phase 1/2 TRANSCEND CLL 004 study, which included adults with relapsed or refractory CLL or SLL after progression on a BTKi and ...

Selected coverage of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, ...

Clinical-stage immuno-oncology company Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has reported encouraging early response ...

The approval was based on the AMPLIFY trial, which evaluated acalabrutinib alongside venetoclax in adults with previously untreated CLL without del(17p) or TP53 mutation.

Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had ...

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are rare in Japan, but a new report affirms the effectiveness of venetoclax (Venclexta) and rituximab (Rituxan) (VenR) in this ...

The accelerated approval was based on data from the phase 1/2 BRUIN trial that included a subset of 108 patients with CLL/SLL. The Food and Drug Administration (FDA) has granted accelerated approval ...

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

The US Food and Drug Administration (FDA) has granted accelerated approval to pirtobrutinib (Jaypirca; Eli Lilly and Company) for third-line or later treatment in adults with chronic lymphocytic ...

The US Food and Drug Administration (FDA) granted accelerated approval for zanubrutinib (Brukinsa) to treat patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The ...

Breyanzi, a CAR-T cell therapy, shows promise for relapsed or refractory CLL and SLL, achieving a 47% response rate and 18% complete remission rate. CAR-T therapy modifies patient T cells to target ...